HORIBA UK will celebrate its 70th anniversary on Stand 715 at IBMS 2023 where delegates are invited to join the celebrations and experience some ‘Joy & Fun’ with HORIBA’s Medical team.

HeartCare Combines Testing Using Both AlloMap Gene Expression Profiling and AlloSure Donor-Derived Cell-Free DNA.

Test reintroduced to the market following regulatory and performance validation for UKCA marking.

Revvity announced the launch of the Fontus™ Automated Liquid Handling Workstation, designed to deliver easier and faster workflows which enable better results for next generation sequencing (NGS) and diagnostic research applications.

Absolute Biotech has announced the reintroduction of SCICONS™ dsRNA antibodies, used to detect dsRNA intermediates of a wide range of viruses, including chikungunya, dengue, hepatitis, rabies, rhinovirus, polio and swine fever.

CareDx’s AlloSure® Lung donor-derived cell-free DNA (dd-cfDNA) molecular testing service has received Medicare coverage.

A landmark study demonstrates that precision oncology medicines could deliver a superior return on Investment for Pharma R&D vs their one size fits all counterparts.

According to two new studies, a pioneering scanning device can instantly reveal an individual’s risk of type 2 diabetes through a non-invasive fingernail reading.

A new clinical trial of a ground-breaking phage-based molecular diagnostic, has been agreed. The trial is aimed at evaluating the performance of the phage assay as a first-line blood-based diagnostic for active pulmonary Tuberculosis.

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, state-of-the-art facility.